Hostname: page-component-77f85d65b8-8wtlm Total loading time: 0 Render date: 2026-03-27T14:47:59.996Z Has data issue: false hasContentIssue false
  • English
  • Français

Neuroendocrine differentiation in head and neck squamous cell carcinoma

Published online by Cambridge University Press:  11 October 2012

V H Schartinger ,
C Falkeis ,
K Laimer ,
G M Sprinzl ,
H Riechelmann ,
M Rasse ,
I Virgolini  and
J Dudás
V H Schartinger*
Affiliation:
Department of Otorhinolaryngology, Medical University Innsbruck, Austria
C Falkeis
Affiliation:
Institute of Pathology, Medical University Innsbruck, Austria
K Laimer
Affiliation:
Department of Maxillofacial Surgery, Medical University Innsbruck, Austria
G M Sprinzl
Affiliation:
Department of Otorhinolaryngology, Medical University Innsbruck, Austria
H Riechelmann
Affiliation:
Department of Otorhinolaryngology, Medical University Innsbruck, Austria
M Rasse
Affiliation:
Department of Maxillofacial Surgery, Medical University Innsbruck, Austria
I Virgolini
Affiliation:
Department of Nuclear Medicine, Medical University Innsbruck, Austria
J Dudás
Affiliation:
Department of Otorhinolaryngology, Medical University Innsbruck, Austria
*
Address for correspondence: Volker H Schartinger, Department of Otorhinolaryngology, Medical University Innsbruck, Anichstrasse 35,6020 Innsbruck, Austria Fax: +43 512 504 23144 E-mail: volker.schartinger@i-med.ac.at
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

Tumours with neuroendocrine differentiation frequently express chromogranin A, synaptophysin and somatostatin receptors. The role of neuroendocrine differentiation in head and neck squamous cell carcinoma is not yet clear.

Method:

The presence of chromogranin A, synaptophysin and somatostatin receptors was studied immunohistochemically in 78 head and neck squamous cell carcinoma specimens.

Results:

Sparse chromogranin A expression was found in 41 per cent, associated with high chromogranin A messenger RNA expression and the presence of dense core granules. Low synaptophysin expression was found in 18 per cent. The highest staining scores were found for somatostatin receptor 5 (82 per cent), followed by somatostatin receptor 1 (69 per cent) and somatostatin receptor 2 (54 per cent), whereas somatostatin receptors 3 and 4 expression was low. Expression was not correlated with tumour stage or survival.

Conclusion:

Cells with neuroendocrine differentiation are sparsely scattered in some head and neck squamous cell carcinomas. Their pathophysiological role is elusive. In contrast, somatostatin receptor and particularly somatostatin receptor 5 expression is frequent in head and neck squamous cell carcinoma. Somatostatin receptor expression is not considered to indicate neuroendocrine differentiation in head and neck squamous cell carcinoma.

Keywords

Head and Neck NeoplasmNeuroendocrine CellsImmunohistochemistry

Information

Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 126 , Issue 12 , December 2012 , pp. 1261 - 1270
Copyright
Copyright © JLO (1984) Limited 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1Modlin, IM, Gustafsson, BI, Moss, SF, Pavel, M, Tsolakis, AV, Kidd, M. Chromogranin A – biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010;17:2427–43CrossRefGoogle ScholarPubMed
2Erickson, LA, Lloyd, RV. Practical markers used in the diagnosis of endocrine tumors. Adv Anat Pathol 2004;11:175–89CrossRefGoogle ScholarPubMed
3Valtorta, F, Pennuto, M, Bonanomi, D, Benfenati, F. Synaptophysin: leading actor or walk-on role in synaptic vesicle exocytosis? Bioessays 2004;26:445–53CrossRefGoogle ScholarPubMed
4Brazeau, P, Vale, W, Burgus, R, Ling, N, Butcher, M, Rivier, J et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77–9CrossRefGoogle ScholarPubMed
5Grozinsky-Glasberg, S, Shimon, I, Korbonits, M, Grossman, AB. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 2008;15:701–20CrossRefGoogle ScholarPubMed
6Rekhtman, N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 2010;134:1628–38CrossRefGoogle ScholarPubMed
7Fujita, T, Yamaji, Y, Sato, M, Murao, K, Takahara, J. Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines. Life Sci 1994;55:1797–806CrossRefGoogle ScholarPubMed
8Nisman, B, Heching, N, Biran, H, Barak, V, Peretz, T. The prognostic significance of circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer. Tumour Biol 2006;27:8–16CrossRefGoogle ScholarPubMed
9Yuan, A, Liu, J, Liu, Y, Cui, G. Chromogranin A-positive tumor cells in human esophageal squamous cell carcinomas. Pathol Oncol Res 2007;13:321–5CrossRefGoogle ScholarPubMed
10Stafford, ND, Condon, LT, Rogers, MJ, MacDonald, AW, Atkin, SL. The expression of somatostatin receptors 1 and 2 in benign, pre-malignant and malignant laryngeal lesions. Clin Otolaryngol Allied Sci 2003;28:314–19CrossRefGoogle ScholarPubMed
11Condon, LT, Stafford, ND, Bedford, KJ, MacDonald, AW, Atkin, SL. The expression of somatostatin receptors 3, 4 and 5 in laryngeal pathology. Eur Arch Otorhinolaryngol 2008;265(suppl 1):S63–7CrossRefGoogle ScholarPubMed
12Laimer, K, Blassnig, N, Spizzo, G, Kloss, F, Rasse, M, Obrist, P et al. Prognostic significance of 14-3-3 sigma expression in oral squamous cell carcinoma (OSCC). Oral Oncol 2009;45:127–34CrossRefGoogle Scholar
13Sagman, U, Mullen, JB, Kovacs, K, Kerbel, R, Ginsberg, R, Reubi, JC. Identification of somatostatin receptors in human small cell lung carcinoma. Cancer 1990;66:2129–333.0.CO;2-T>CrossRefGoogle ScholarPubMed
14Li, M, Li, W, Kim, HJ, Yao, Q, Chen, C, Fisher, WE. Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR. J Surg Res 2004;119:130–7CrossRefGoogle ScholarPubMed
15Glueckert, R, Bitsche, M, Miller, JM, Zhu, Y, Prieskorn, DM, Altschuler, RA et al. Deafferentation-associated changes in afferent and efferent processes in the guinea pig cochlea and afferent regeneration with chronic intrascalar brain-derived neurotrophic factor and acidic fibroblast growth factor. J Comp Neurol 2008;507:1602–21CrossRefGoogle ScholarPubMed
16Schmutzhard, J, Glueckert, R, Bitsche, M, Abraham, I, Falkeis, C, Schwentner, I et al. The cochlea in fetuses with neural tube defects. Int J Dev Neurosci 2009;27:669–76CrossRefGoogle ScholarPubMed
17Howe, MC, Chapman, A, Kerr, K, Dougal, M, Anderson, H, Hasleton, PS. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology 2005;46:195–201CrossRefGoogle ScholarPubMed
18Banks, ER, Frierson, HF Jr, Mills, SE, George, E, Zarbo, RJ, Swanson, PE. Basaloid squamous cell carcinoma of the head and neck. A clinicopathologic and immunohistochemical study of 40 cases. Am J Surg Pathol 1992;16:939–46CrossRefGoogle ScholarPubMed
19Wieneke, JA, Thompson, LD, Wenig, BM. Basaloid squamous cell carcinoma of the sinonasal tract. Cancer 1999;85:841–543.0.CO;2-6>CrossRefGoogle ScholarPubMed
20Abbona, G, Papotti, M, Viberti, L, Macri, L, Stella, A, Bussolati, G. Chromogranin A gene expression in non-small cell lung carcinomas. J Pathol 1998;186:151–63.0.CO;2-7>CrossRefGoogle ScholarPubMed
21Kharmate, G, Rajput, PS, Watt, HL, Somvanshi, RK, Chaudhari, N, Qiu, X et al. Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in the presence of somatostatin receptor 5 modulate signaling pathways. Endocrinology 2011;152:931–45CrossRefGoogle ScholarPubMed
22Miederer, M, Seidl, S, Buck, A, Scheidhauer, K, Wester, HJ, Schwaiger, M et al. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68 Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009;36:48–52CrossRefGoogle Scholar
23Culler, MD, Oberg, K, Arnold, R, Krenning, EP, Sevilla, I, Diaz, JA. Somatostatin analogs for the treatment of neuroendocrine tumors. Cancer Metastasis Rev 2011;30(suppl 1):9–17CrossRefGoogle ScholarPubMed
24Anthony, L, Freda, PU. From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin 2009;25:2989–99CrossRefGoogle ScholarPubMed
25Kvols, LK, Woltering, EA. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs 2006;17:601–8CrossRefGoogle ScholarPubMed